Stifel Financial’s Vanda Pharmaceuticals VNDA Stock Holding History

Stifel Financial’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,300	Closed	-$142K	–	2983
2019 Q2	$142K	Buy	+10,300	New	+$164K	﹤0.01%	2782

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Stifel Financial's VNDA Position: Q3 2019 in Review

Stifel Financial sold out of Vanda Pharmaceuticals (VNDA) in Q3 2019, closing a stake of 10,300 shares — an estimated $142K sold.

Stifel Financial first reported a position in VNDA in Q2 2019 and held it in 1 quarter. The position peaked at $142K in Q2 2019. 168 funds tracked by Wall St. Rank hold VNDA as of Q3 2019.

Stifel Financial reported no remaining Vanda Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Stifel Financial sold 10,300 Vanda Pharmaceuticals shares in Q3 2019, an estimated $142K.
Stifel Financial first reported a position in Vanda Pharmaceuticals in Q2 2019 and held it in 1 quarter.
Stifel Financial's Vanda Pharmaceuticals position peaked at $142K in Q2 2019.
168 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2019.

Based on Stifel Financial's 13F filing for Q3 2019, filed 13 Nov 2019.